SRPT insider transactions
Sarepta Therapeutics Inc. (SRPT) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for SRPT
- Director Boor Kathryn Jean was granted 16,875 shares, increasing direct ownership by 204% to 25,138 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Mayo Stephen was granted 16,875 shares, increasing direct ownership by 956% to 18,640 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Wigzell Hans Lennart Rudolf was granted 16,875 shares, increasing direct ownership by 67% to 42,098 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Behrens M Kathleen was granted 16,875 shares, increasing direct ownership by 9% to 214,357 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Connelly Deirdre P was granted 16,875 shares, increasing direct ownership by 323% to 22,100 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Nicaise Claude was granted 16,875 shares, increasing direct ownership by 54% to 48,407 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Chambers Michael Andrew was granted 16,875 shares, increasing direct ownership by 158% to 27,535 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Barry Richard was granted 16,875 shares, increasing direct ownership by 0.57% to 2,983,542 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Operating Officer Estepan Ian Michael covered exercise/tax liability with 1,097 shares, decreasing direct ownership by 0.54% to 201,983 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 256 shares, decreasing direct ownership by 0.19% to 135,064 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- President, R&D and Tech Ops Rodino-Klapac Louise covered exercise/tax liability with 948 shares, decreasing direct ownership by 0.42% to 225,323 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Mayo Stephen sold $123,208 worth of shares (7,239 units at $17.02), decreasing direct ownership by 80% to 1,765 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- EVP, General Counsel Rothfuss Cristin covered exercise/tax liability with 974 shares, decreasing direct ownership by 0.70% to 137,544 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 275 shares, decreasing direct ownership by 0.20% to 135,320 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- EVP, General Counsel Rothfuss Cristin covered exercise/tax liability with 830 shares, decreasing direct ownership by 0.60% to 138,518 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- President, R&D and Tech Ops Rodino-Klapac Louise covered exercise/tax liability with 1,399 shares, decreasing direct ownership by 0.61% to 226,271 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Operating Officer Estepan Ian Michael covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 0.79% to 203,080 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- EVP, General Counsel Rothfuss Cristin covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.29% to 139,348 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 450 shares, decreasing direct ownership by 0.33% to 135,595 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Operating Officer Estepan Ian Michael converted options into 8,125 shares and covered exercise/tax liability with 4,176 shares, increasing direct ownership by 2% to 204,699 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- President, R&D and Tech Ops Rodino-Klapac Louise converted options into 8,125 shares and covered exercise/tax liability with 4,485 shares, increasing direct ownership by 2% to 227,670 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Operating Officer Estepan Ian Michael exercised 7,450 shares at a strike of $13.71, increasing direct ownership by 4% to 200,750 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- SEC Form 4 filed by Chief Operating Officer Estepan Ian Michael4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- SEC Form 4 filed by President, R&D and Tech Ops Rodino-Klapac Louise4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Nicaise Claude exercised 10,500 shares at a strike of $13.71 and covered exercise/tax liability with 6,780 shares, increasing direct ownership by 13% to 31,532 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Behrens M Kathleen exercised 10,500 shares at a strike of $13.71 and covered exercise/tax liability with 6,494 shares, increasing direct ownership by 2% to 197,482 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- SEC Form 4 filed by Director Chambers Michael Andrew4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Operating Officer Estepan Ian Michael sold $294,202 worth of shares (13,187 units at $22.31), decreasing direct ownership by 6% to 193,300 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 158 shares, decreasing direct ownership by 0.12% to 136,045 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Executive Officer Ingram Douglas S was granted 539,084 shares, increasing direct ownership by 138% to 929,391 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- EVP, General Counsel Rothfuss Cristin covered exercise/tax liability with 229 shares, decreasing direct ownership by 0.16% to 139,756 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- President, R&D and Tech Ops Rodino-Klapac Louise covered exercise/tax liability with 4,582 shares, decreasing direct ownership by 2% to 224,030 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Operating Officer Estepan Ian Michael was granted 143,875 shares, increasing direct ownership by 230% to 206,487 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- EVP, General Counsel Rothfuss Cristin was granted 118,875 shares, increasing direct ownership by 563% to 139,985 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- President, R&D and Tech Ops Rodino-Klapac Louise was granted 143,875 shares, increasing direct ownership by 170% to 228,612 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Financial Officer Wong Ryan Ho-Yan was granted 118,875 shares, increasing direct ownership by 686% to 136,203 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- SEC Form 4 filed by Chief Tech Ops Officer Arif Bilal4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- SEC Form 4 filed by Chief Operating Officer Estepan Ian Michael4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- SEC Form 4 filed by President, R&D and Tech Ops Rodino-Klapac Louise4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 327 shares, decreasing direct ownership by 2% to 17,328 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- New insider Wong Ryan Ho-Yan claimed ownership of 17,655 shares (SEC Form 3)3 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Barry Richard exercised 12,350 shares at a strike of $32.63, increasing direct ownership by 0.42% to 2,966,667 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Barry Richard exercised 20,246 shares at a strike of $19.23, increasing direct ownership by 0.69% to 2,954,317 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Nicaise Claude exercised 9,746 shares at a strike of $25.18 and sold $248,203 worth of shares (2,491 units at $99.64), increasing direct ownership by 35% to 27,812 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Boor Kathryn Jean was granted 2,383 shares, increasing direct ownership by 41% to 8,263 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Connelly Deirdre P was granted 2,383 shares, increasing direct ownership by 84% to 5,225 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Chambers Michael Andrew was granted 2,383 shares, increasing direct ownership by 29% to 10,660 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Wigzell Hans Lennart Rudolf was granted 2,383 shares, increasing direct ownership by 10% to 25,223 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Barry Richard was granted 2,383 shares, increasing direct ownership by 0.08% to 2,934,071 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Tech Ops Officer Arif Bilal covered exercise/tax liability with 523 shares and was granted 8,276 shares, increasing direct ownership by 31% to 32,500 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Customer Officer Murray Dallan converted options into 5,500 shares, covered exercise/tax liability with 3,733 shares and was granted 8,276 shares, increasing direct ownership by 36% to 38,202 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Head of R&D, CSO Rodino-Klapac Louise converted options into 5,500 shares, covered exercise/tax liability with 3,463 shares and was granted 8,276 shares, increasing direct ownership by 14% to 84,631 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Nicaise Claude was granted 2,383 shares, increasing direct ownership by 13% to 20,557 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- EVP, General Counsel Rothfuss Cristin was granted 8,276 shares and covered exercise/tax liability with 491 shares, increasing direct ownership by 58% to 21,110 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Mayo Stephen was granted 2,383 shares, increasing direct ownership by 36% to 9,004 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Financial Officer Estepan Ian Michael converted options into 5,500 shares, covered exercise/tax liability with 3,941 shares and was granted 8,276 shares, increasing direct ownership by 19% to 62,612 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Director Behrens M Kathleen was granted 2,383 shares, increasing direct ownership by 1% to 193,476 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Financial Officer Estepan Ian Michael converted options into 17,500 shares and covered exercise/tax liability with 9,679 shares, increasing direct ownership by 17% to 52,777 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Chief Tech Ops Officer Arif Bilal converted options into 17,500 shares and covered exercise/tax liability with 9,035 shares, increasing direct ownership by 52% to 24,747 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- EVP, General Counsel Rothfuss Cristin covered exercise/tax liability with 1,478 shares, decreasing direct ownership by 11% to 11,847 units (SEC Form 4)4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)